Brain metastases from NSCLC:radiation therapy in the era of targeted therapies
10.3781/j.issn.1000-7431.2024.2312-0676
- VernacularTitle:非小细胞肺癌脑转移:靶向治疗时代的放射治疗
- Author:
Xuchang LI
1
;
Yangchen XIA
1
;
Fangfang LIU
1
;
Xu YUAN
1
;
Qian CHU
1
Author Information
1. 华中科技大学同济医学院附属同济医院胸部肿瘤科,湖北 武汉 430030
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
Brain metastases;
Radiotherapy;
Targeted therapy
- From:
Tumor
2024;44(6):621-630
- CountryChina
- Language:Chinese
-
Abstract:
Brain is one of the most common metastatic sites for lung cancer,and brain metastases seriously affect the clinical prognosis of patients with non-small cell lung cancer(NSCLC).In the era of targeted therapy,a series of tyrosine kinase inhibitors(TKIs)have brought significant survival benefits to patients with NSCLC.However,this has also led to an increasing number of long-term survivors experiencing brain metastases.As a traditional treatment of brain metastases,radiotherapy can effectively control intracranial symptoms and improve the clinical condition of patients.In recent years,with the increased penetration of TKIs into the central nervous system,the intracranial control of NSCLC patients with brain metastases receiving TKI treatment has significantly improved,and the role of radiotherapy in patients with brain metastases has been gradually challenged.Therefore,how to rationally choose TKIs and radiotherapy to treat NSCLC brain metastases has become an important issue that needs to be addressed urgently.
